New Adjunctive Therapy for Antibody-Mediated Rejection
Article Sidebar
Main Article Content
Abstract
Antibody-mediated rejection is one of the most serious complications after kidney transplantation. Rejection is the second most common cause of graft lost following death with functioning graft. The current standard treatment consists of combined plasmapheresis and intravenous immunoglobulin, which aims at removing alloantibody. The recent systematic review revealed variable responses among different studies ranging between 0 - 83%. With better understanding of the complex mechanisms underlying antibody-mediated rejection, other novel adjunctive therapy has been increasingly used in addition to the standard treatment. Current promising adjunctive therapies are rituximab which targets B-cells, bortezomib which targets plasma cells and eculizumab which targets the complement system. Alkylating agents and anti-thymocyte globulin have been proven ineffective.
Other treatments that may add benefits to the standard treatment include imlifidase, interleukin-6 receptor antagonist, interleukin-6 antibody, and CD-38 monoclonal inhibitor.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This article is published under CC BY-NC-ND 4.0 license, which allows for non-commercial reuse of the published paper as long as the published paper is fully attributed. Anyone can share (copy and redistribute) the material in any medium or format without having to ask permission from the author or the Nephrology Society of Thailand.
References
System USRD. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States [Internet]. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2020; Available from: https://adr.usrds.org/2020
สุรสีห์ พร้อมมูล. รายงานข้อมูลการปลูกถ่ายอวัยวะประจำปี พ.ศ.2562; Bangkok Medical Publisher Ltd. Part.; 2563.
Yu ASL, Chertow GM, Luyckx VA, Marsden PA, Skorecki K, Taal MW. Brenner & Rector’s the kidney [Internet]. 2020 [cited 2021 Aug 22]. Available from: https://www.clinicalkey.com/dura/browse/bookChapter/3-s2.0-C20161038580
Loupy A, Haas M, Roufosse C, Naesens M, Adam B, Afrouzian M, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20(9):2318–31.
Racusen LC, Haas M. Antibody-Mediated Rejection in Renal Allografts: Lessons from Pathology. Clin J Am Soc Nephrol. 2006;1(3):415–20.
Kim M, Martin ST, Townsend KR, Gabardi S. Antibody-Mediated Rejection in Kidney Transplantation: A Review of Pathophysiology,
Diagnosis, and Treatment Options. Pharmacotherapy. 2014;34(7):733–44.
Sablik KA, Clahsen-van Groningen MC, Looman CWN, Damman J, Roelen DL, van Agteren M, et al. Chronic-active antibody-mediated rejection with or without donor-specific antibodies has similar histomorphology and clinical outcome - a retrospective study. Transpl Int. 2018 ;31(8):900–8.
Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int. 2012 ;25(6):623–32.
Lefaucheur C, Nochy D, Andrade J, Verine J, Gautreau C, Charron D, et al. Comparison of Combination Plasmapheresis/IVIg/Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection. Am J Transplant. 2009;9(5):1099–107.
Roberts DM, Jiang SH, Chadban SJ. The Treatment of Acute Antibody-Mediated Rejection in Kidney Transplant Recipients—A Systematic Review. Transplantation. 2012;94(8):775–83.
Velidedeoglu E, Cavaillé-Coll MW, Bala S, Belen OA, Wang Y, Albrecht R. Summary of 2017 FDA Public Workshop: Antibodymediated
Rejection in Kidney Transplantation. Transplantation. 2018;102(6):e257–64.
Special Issue: KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Transplant. 2009;9:S1–155
Böhmig GA, Eskandary F, Doberer K, Halloran PF. The therapeutic challenge of late antibody–mediated kidney allograft rejection. Transpl Int. 2019;32(8):775-88.
Hamilton P, Harris R, Mitra S. Immunoadsorption Techniques and Its Current Role in the Intensive Care Unit. In: Karkar A, editor. Aspects in Continuous Renal Replacement Therapy [Internet]. IntechOpen; 2019 [cited 2021 Aug 28]. Available from: https://www.intechopen.com/books/aspects-incontinuous-renal-replacement-therapy/immunoadsorptiontechniques-and-its-current-role-in-the-intensive-care-unit
Böhmig GA, Wahrmann M, Regele H, Exner M, Robl B, Derfler K, et al. Immunoadsorption in Severe C4d-Positive Acute Kidney Allograft Rejection: A Randomized Controlled Trial. Am J Transplant. 2007;7(1):117–21.
Faguer S, Kamar N, Guilbeaud-Frugier C, Fort M, Modesto A, Mari A, et al. Rituximab Therapy for Acute Humoral Rejection After Kidney Transplantation. Transplantation. 2007;83(9):1277–80.
Mulley WR, Hudson FJ, Tait BD, Skene AM, Dowling JP, Kerr PG, et al. A Single Low-Fixed Dose of Rituximab to Salvage Renal Transplants From Refractory Antibody-Mediated Rejection. Transplantation. 2009;87(2):286–9.
Kaposztas Z, Podder H, Mauiyyedi S, Illoh O, Kerman R, Reyes M, et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant. 2009;23(1):63–73.
Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM. A Randomized, Prospective Trial of Rituximab for Acute Rejection in Pediatric Renal Transplantation. Am J Transplant. 2008;8(12):2607–17.
Sautenet B, Blancho G, Büchler M, Morelon E, Toupance O, Barrou B, et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation. 2016;100(2):391–9.
Moreso F, Crespo M, Ruiz JC, Torres A, Gutierrez-Dalmau A, Osuna A, et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. Am J Transplant. 2018;18(4):927–35.
Enna SJ, Bylund DB, Elsevier Science (Firm). XPharm: the comprehensive pharmacology reference [Internet]. Amsterdam; Boston: Elsevier; 2008 [cited 2021 Aug 29]. Available from: http://www.sciencedirect.com/science/referenceworks/9780080552323
Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, et al. Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production: Proteasome Inhibition of Alloantibody Production. Am J Transplant. 2008;9(1):201–9.
Walsh RC, Brailey P, Girnita A, Alloway RR, Shields AR, Wall GE, et al. Early and Late Acute Antibody-Mediated Rejection Differ Immunologically and in Response to Proteasome Inhibition. Transplantation. 2011;91(11):1218–26.
Waiser J, Budde K, Schutz M, Liefeldt L, Rudolph B, Schonemann C, et al. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrol Dial Transplant. 2012;27(3):1246–51.
Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2018;29(2):591–605.
Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park). 2004;14 Suppl 11:14-21.
Schinstock CA, Mannon RB, Budde K, Chong AS, Haas M, Knechtle S, et al. Recommended Treatment for Antibodymediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation. 2020;104(5):911–22.
Tan EK, Bentall A, Dean PG, Shaheen MF, Stegall MD, Schinstock CA. Use of Eculizumab for Active Antibodymediated Rejection That Occurs Early Post–kidney Transplantation: A Consecutive Series of 15 Cases. Transplantation. 2019;103(11):2397–404.
Cornell LD, Schinstock CA, Gandhi MJ, Kremers WK, Stegall MD. Positive Crossmatch Kidney Transplant Recipients Treated With Eculizumab: Outcomes Beyond 1 Year: Late Outcomes After Eculizumab. Am J Transplant. 2015;15(5):1293–302.
Huang E, Jordan SC. Imlifidase as a Potential Treatment for Antibody-Mediated Rejection. Curr Transplant Rep. 2021;8(2):157–61.
Jordan SC, Lorant T, Choi J, Kjellman C, Winstedt L, Bengtsson M, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017;377(5):442–53.
Lefaucheur C, Loupy A, Vernerey D, Duong-Van-Huyen J-P, Suberbielle C, Anglicheau D, et al. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet. 2013;381(9863):313–9.
Waiser J, Duerr M, Budde K, Rudolph B, Wu K, Bachmann F, et al. Treatment of Acute Antibody-Mediated Renal Allograft Rejection With Cyclophosphamide. Transplantation. 2017;101(10):2545–52.
Sebba A. Tocilizumab: The first interleukin-6-receptor inhibitor. Am J Health Syst Pharm. 2008;65(15):1413–8.
Choi J, Aubert O, Vo A, Loupy A, Haas M, Puliyanda D, et al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant. 2017;17(9):2381–9.
Doberer K, Duerr M, Halloran PF, Eskandary F, Budde K, Regele H, et al. A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol. 2021;32(3):708
Jordan S, Vescio R, Toyoda M, Ammerman N, Huang E, Peng A, et al. Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient. Am J Transplant. 2019;19.
Hu Y, Turner MJ, Shields J, Gale MS, Hutto E, Roberts BL, et al. Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model. Immunology. 2009;128(2):260–70.
Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection. Clin Transplant. 2004;18 (6):759–61.
Jirasiritham S, Khunprakant R, Techawathanawanna N, Jirasiritham Si, Mavichak V. Treatment of Simultaneous Acute Antibody-Mediated Rejection and Acute Cellular Rejection With Alemtuzumab in Kidney Transplantation: A Case Report. Transplant Proc. 2010;42(3):987–9.
Locke JE, Zachary AA, Haas M, Melancon JK, Warren DS, Simpkins CE, et al. The Utility of Splenectomy as Rescue Treatment for Severe Acute Antibody Mediated Rejection. Am J Transplant. 2007;7(4):842–6.